Hua Xin Yi Nuo
One-Stop Preclinical R&D Solution for Innovative Drugs
Positioning: A full-process technology empowerment platform from target discovery to IND submission<
Core Commitment: Using Al+ high-throughput cutting-edge animal models + GLP-compliant hardware, we’re tackling the pain points of new drug development—long cycles, high costs, and low success rates.
I. Directly address industry pain points and seize the initiative in R&D.
New drug development is facing multiple challenges, and our platform provides precisely targeted solutions:
● Pressure from cycles and costs: Traditional R&D typically takes 10 to 15 years and often costs over ten million yuan, with high trial-and-error costs. We can significantly shorten the development cycle, reduce costs, and improve the success rate.
● Low conversion efficiency: The preclinical-to-clinical translation rate is less than 10%; however, by achieving a human response prediction accuracy of over 90%, we’ve significantly boosted the success rate of translation.
● Model and Facility Limitations: Traditional two-dimensional cell models fail to reflect the real microenvironment, and animal experiments suffer from significant species differences. Moreover, most biotech companies lack GLP-compliant toxicology and laboratory animal facilities. To address these challenges, we offer a multi-level validation system that integrates “Al + organoids + zebrafish + GLP-compliant laboratory animals.”
II. Core Technologies: Five Cutting-Edge Modules to Build a Closed R&D Loop
1. AI Drug Design Platform—A “Accelerator” for R&D
● Core breakthrough:
The deep learning model GATomics integrates single-cell multi-omics data to identify novel disease targets.
● Technological Advantages:
Target prioritization: Protein structure prediction + binding site analysis for precise identification of functional sites;
Molecular generation: AI automatically designs peptide/small-molecule structures that meet pharmaceutical requirements;
ADMET Prediction: Early assessment of absorption, metabolism, and toxicity significantly improves the hit rate of candidate molecules compared to traditional methods.
2. Organoid High-Throughput Platform—“Human Microenvironment” Simulator
● Core breakthrough:
Comprehensive coverage of all types of organoids, including tumor PDOs, liver/kidney organoids, skin/neural organoids, heart organoids, and intestinal organoids.
● Technological Advantages:
Lego-A Fully Automated Drug Screening Platform: Enables automated drug screening, fully automated ultra-long-term organoid culture, and maintains tissue heterogeneity.
Multi-type high-throughput microfluidic chips: Support high-throughput 3D culture, with a maximum screening capacity of up to 19,800 samples per run;
Enrich the organoid model library: Realistically simulates the microenvironment within the human body, with clinical relevance exceeding 90%; costs are significantly lower than those of animal models.
3. Zebrafish Screening Platform—In Vivo Validation of “High-Performance Tools”
● Core breakthrough:
By addressing the core challenges of traditional animal experiments—long duration, high costs, and significant species differences that make it difficult to translate results into clinical applications—we have developed an in vivo validation system featuring "high throughput + high homology," enabling a leap in drug screening efficiency from "monthly" to "daily." This system fills the critical gap between conventional in vitro models and traditional animal studies.
● Technological Advantages:
High Homology and Clinical Relevance: Zebrafish exhibit over 83% homology with human drug targets, enabling experimental results to more accurately reflect human drug responses and providing reliable data support for subsequent research and development.
Visualization and Precise Monitoring: The transparent nature of embryos enables fluorescent labeling and three-dimensional real-time tracking, allowing for intuitive observation of the dynamic effects of drugs on organ development, blood flow, neural behavior, and other processes.
Standardization of automated support: Equipped with automated feeding systems, automatic portioning systems, and automated high-throughput experimental systems to minimize human intervention and ensure the consistency and reproducibility of experimental data.
Over 100 zebrafish disease models: the largest zebrafish disease model library in Northwest China, enabling efficient and comprehensive screening and validation of diseases.
Type | Disease model | Type | Disease model |
Cardiovascular and cerebrovascular diseases Disease | Endothelial injury model in vessels | Liver and kidney-related Disease | Alcoholic fatty liver model |
Platelet Aggregation Thrombus Model | Non-alcoholic fatty liver disease model | ||
Liver fibrosis model | |||
Erythrocytic thrombosis model | |||
Thrombus model of Qi stagnation and blood stasis type | Acute liver injury model | ||
Heart failure model | Liver hemorrhage model | ||
Myocardial Injury Model | Kidney injury model | ||
Bradycardia model | Skin-related Disease | Skin injury model | |
Cardiac hemorrhage model | Skin Scar Model | ||
Cerebral hemorrhage model | Skin inflammation model | ||
Cerebral ischemia/cerebral thrombosis model | Skin Wrinkle Model | ||
Anemia model | Radiation model | ||
Oxidative Damage Model | Acne model | ||
Audiovisual Disease | Apoptosis model of retinal cells | Musculoskeletal Disease | Tissue Regeneration/Wound Injury Model |
Drug-induced ocular injury model | |||
Joint cartilage injury model | |||
Retinal Development Injury Model | Osteoporosis model | ||
Wet age-related macular degeneration model | Muscle injury model | ||
Ear injury model | Bone sclerosis model | ||
Gastrointestinal metabolism System class Disease | Hyperglycemia model | Neurological disorders Disease | Epilepsy model |
Hyperlipidemia model | Alzheimer's disease | ||
Drunk model | Peripheral nerve injury model | ||
Axonal injury model | |||
Uric acid model | |||
Diabetes model | Radiation-induced brain injury model | ||
Spleen Yang Deficiency Model | Central Nervous System Injury Model | ||
Gastrointestinal Mucosal Injury Model | Peripheral motor neuron injury model | ||
Constipation model | Myelin Damage Model | ||
Parkinson's disease model | |||
Other categories Disease | Bacterial Pneumonia Disease Model | Depression model | |
Viral Pneumonia Disease Model | Insomnia model | ||
Immunocompromised model | Anxiety Model | ||
Special Disease | Congenital Dilated Cardiomyopathy Model | Syndactyly model | |
Short-finger syndrome model | Distal Dysplasia Model | ||
Craniosynostosis model | Adult-onset myasthenia gravis model | ||
Cystic fibrosis model | |||
4. GLP Safety Assessment and Large Animal Testing Platform—A Compliance “Keystone”
● Core breakthrough:
Establish a GLP-compliant system covering “all types of toxicological studies plus multi-species animal models,” addressing the pain point that most biotech companies and research teams lack well-equipped toxicology and large-animal testing facilities. This system will provide end-to-end, compliant data support—from early toxicological alerts to cross-regional registration submissions—and fill the gap in OECD GLP compliance in Northwest China.
● Technological Advantages:
Comprehensive toxicology studies covered: We can conduct a full range of studies, including general toxicology, genotoxicity, reproductive and developmental toxicity, carcinogenicity, inhalation toxicology, medical device toxicology, veterinary drug toxicology, and pesticide toxicology, thereby meeting the safety evaluation needs at all stages of drug development.
Diversified animal model support: covering zebrafish, mice and rats, laboratory dogs, non-human primates, and more.
Pigs, cattle, sheep, horses, and other animals are housed in facilities that meet AAALAC International’s animal welfare standards and are monitored around the clock by a dedicated team of veterinarians.
Professional Team and Hardware Support: We have a seasoned GLP expert team and are equipped with a full suite of analytical facilities, including LC-MS instruments, flow cytometers, and automated equipment for pathological tissue sectioning and staining, ensuring the accuracy of experimental data and timely delivery of reports.
5. Digital Microfluidics Technology—A “Revolution” in Ultra-High Throughput
● Core breakthrough:
Breaking through the limitations of traditional experiments—such as low throughput, large sample consumption, and heavy reliance on manual operations—we have achieved precise control of nanoliter-scale liquids and three-dimensional microenvironment simulation. This has enabled us to build an ultra-high-throughput experimental system featuring “tens of thousands of reaction chambers on a single chip plus fully automated workflows,” thereby driving the transition of applications such as drug screening and organoid construction from “batch-based” approaches to “large-scale parallel” ones.
● Technological Advantages:
Ultra-high throughput and miniaturization: A single chip features 19,800 independent reaction chambers, enabling parallel high-throughput testing of drug/concentration combinations simultaneously. This significantly reduces both spatial footprint and reagent consumption, greatly enhancing experimental efficiency and accuracy.
Precise Control and Microenvironment Simulation: Supports liquid manipulation accuracy spanning a range from nanoliters to milliliters—covering over six orders of magnitude—and enables precise generation of drug gradients. By reconstructing the microfluidic space in three dimensions, it accurately simulates the microenvironment of human tissues, thereby enhancing the correlation between experimental results and in vivo conditions.
III. Real-World Case Studies: From Technology to Tangible Outcomes
Case 1: Oncology Drug Development—Successfully Advancing IND Submission
● Project Background: Development of a Novel Targeted Anti-Tumor Drug
● R&D Process:
1. AI Screening: 10 Candidate Compounds Designed Based on the GATomics Model
2. PDO Antibiotic Susceptibility Testing: Patient-derived organoids were used for validation to identify three key molecular targets.
3. Zebrafish Toxicology: Eliminating Potential Risks and Screening for Active Molecules
4. GLP bridging: Standardized toxicological assessment, with data meeting submission requirements.
Results: Compound ZR-542 has successfully advanced to the IND stage, with a culture cycle of 6 weeks and a prediction accuracy rate of 94%.
Case 2: Cardiovascular Drug Screening—Proactively Mitigating Safety Risks
● Project Objectives: Screening for antibody drugs that regulate cardiac rhythm by targeting calcium channels
● Technical Path: Organoid calcium signaling monitoring → Human-derived cardiomyocyte model → Zebrafish cardiac recording
● R&D achievements:
5. Three active compounds—MEK-I, C25, and A11—were identified, with a heart failure relief rate ranging from 60% to 90%.
6. Identify in advance the risk of MEK-I dose-dependent heart rate suppression to avoid GLP study failures and save on later-stage funding investments.
More fields
As an institution in Shaanxi Province that has obtained NMPA drug GLP certification and completed its qualification re-examination and scope expansion in 2024, Guorui Yinuo has built a “global + domestic” dual-compliance service capability in the pharmaceutical sector.
The one-stop service platform for veterinary drugs—GLP/GCP—is a specialized service provider that offers an integrated solution—from non-clinical evaluation to clinical trials and registration submission—aligned with both the Ministry of Agriculture and Rural Affairs’ GLP/GCP standards for veterinary drugs and the international OECD GLP standards, covering the entire R&D process for veterinary pharmaceuticals. At its core, this platform addresses the key pain points faced by companies, including long R&D cycles, high compliance barriers, and fragmented resources.
As the only organization in the Northwest region to have obtained OECD GLP certification in the pesticide field, Guorui Yinuo passed the international assessment with a zero-defect record. Relying on its compliance credentials, comprehensive technological capabilities across the entire value chain, and high-standard laboratory platform, Guorui Yinuo provides integrated solutions for global pesticide companies—from research and development all the way through registration.
Relying on the OECD GLP zero-defect certification qualification, chemical test data can be globally recognized and simultaneously comply with both domestic and international chemical regulatory requirements as well as relevant requirements of the Ministry of Ecology and Environment, efficiently supporting needs such as chemical registration and export declarations.
Shaanxi Guorui Xinchuang Medical Technology Co., Ltd. is an independent, third-party clinical preclinical safety evaluation research institution for medical devices. It was registered and established in June 2020 in the Airport New City and is currently the most comprehensive medical device safety evaluation institution in Northwest China. The company primarily provides product safety evaluation services to R&D enterprises specializing in Class II and Class III medical devices.
A full-process technology empowerment platform from target discovery to IND submission
Early Toxicity Prediction and Screening
Early toxicity screening is an essential and indispensable step in the new drug development process. Early termination of compounds that show no development potential can save sponsor substantial amounts of manpower, resources, and time. We offer sponsor comprehensive early toxicity screening services, including early genotoxicity assessment, early general toxicity assessment, and early reproductive and developmental toxicity assessment.
We are equipped with specialized instruments and devices, including flow cytometers, microplate readers, fluorescence microscopes, and PCR machines. These resources enable us to establish animal models for diseases affecting the tumor, cardiovascular, respiratory, metabolic, and urinary systems, and to conduct comprehensive and systematic preclinical studies on drug efficacy and mechanisms at multiple levels.
Contact phone number
Ms. Li:+86 15760970681
Mr. Su:+86 19991001701
Landline:+86-29-33656828
Company Address
4th Floor, Unit C. Building 9. Small and Medium-sized
Enterprise Park, Airport Industrial Zone Airport New Ciy,Xixian New Area, Shaanxi Province
©2026 Xixian New Area Guorui Yinuo Drug Safety Evaluation and Research Co., Ltd.
WhatsApp：8613940397353
Email：hr-xian@grglp.com
Landline：862933656828
Mr. Su：8619991001701
Ms. Li：8615760970681